Every 10-Q that SenesTech, Inc. (SNES) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SNES and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNES filings page.
SenesTech, Inc. reports higher sales but continued losses for the quarter ended June 30, 2026. Revenues were $770,000, up from $625,000 a year earlier, driven mainly by Evolve fertility-control products, which contributed 86% of quarterly revenue and increasingly flow through e-commerce channels such as Amazon. Six‑month revenue reached $1.3 million.
Gross margin strengthened to 73.6% as the company shifted Amazon sales to direct management, capturing higher unit pricing while recording marketplace fees in operating expenses. Operating expenses rose to $2.4 million in the quarter, reflecting leadership succession costs, higher professional fees, and commercialization investments, leading to a net loss of $1.8 million for the quarter and $3.9 million year‑to‑date.
Cash and cash equivalents were $5.1 million, down from $7.6 million at year‑end, after using $3.6 million in operating cash during the first half. Management expects existing cash plus anticipated revenue to fund operations only through the end of the first quarter of fiscal 2027 and plans to grow revenue, manage expenses, and raise additional capital, including through its at‑the‑market equity facility with roughly $7.3 million of remaining capacity. A prior legal dispute with Liphatech was settled and dismissed. Significant outstanding stock options and warrants represent potential future dilution.
SenesTech, Inc. reported first-quarter 2026 results with revenue of $493,000, up slightly from $485,000 a year earlier, as its Evolve fertility-control products grew to 85% of sales while ContraPest declined. Gross profit was $338,000, for a margin of 68.6%, reflecting improved production efficiency and pricing.
The company posted a net loss of $2.1 million, compared with $1.7 million in the prior-year quarter, driven mainly by higher selling, general and administrative expenses, including legal costs tied to a settled litigation matter and severance and search expenses related to leadership changes. Operating cash use was $1.9 million.
Cash, cash equivalents and short-term investments totaled $6.8 million as of March 31, 2026, versus $8.6 million at year-end 2025. Management expects existing cash and anticipated revenue to fund operations into the third quarter of 2027. During the quarter, SenesTech raised $173,000 net via its at-the-market equity facility and ended with total assets of $11.1 million and stockholders’ equity of $7.7 million.
SenesTech (SNES) filed its Q3 2025 report, highlighting improved growth and liquidity. Revenue reached $690,000, up 43% year over year, driven largely by the Evolve product line, while ContraPest declined. Gross profit was $433,000 with a 62.8% margin in the quarter; for the first nine months, revenue was $1.8 million with a 64.2% gross margin. Net loss narrowed to $1.3 million for the quarter.
Management reports that prior substantial doubt about continuing as a going concern has been alleviated. During 2025, financing transactions generated $13.2 million in net proceeds, and cash, cash equivalents and short‑term investments totaled $10.2 million as of September 30, 2025, supporting at least the next 12 months. The company ended the period with 5,223,015 shares outstanding as of November 7, 2025. Operating cash use improved versus last year, and higher interest income reflected larger average balances.
Evolve Rat and Evolve Mouse now comprise the majority of sales across e‑commerce, professional, and retail channels. Operating expenses were stable year over year as cost containment offset higher legal and franchise fees. An at‑the‑market program added $2.7 million year to date, and warrant exercises added $10.5 million, bolstering liquidity while the company works toward higher‑margin growth.